(Q35043094)

6 August 2017

1 reference

title

Intravascular adenoviral agents in cancer patients: lessons from clinical trials (English)

1 reference

6 August 2017

1 reference

Tony Reid

1

1 reference

6 August 2017

Robert Warren

series ordinal

2

1 reference

6 August 2017

David Kirn

series ordinal

3

1 reference

6 August 2017

publication date

1 December 2002

1 reference

6 August 2017

1 reference

6 August 2017

volume

9

1 reference

6 August 2017

issue

12

1 reference

6 August 2017

page(s)

979-986

1 reference

Cancer gene therapy: fringe or cutting edge?

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Gene therapy: adenovirus vectors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Gene therapy for cancer: what have we done and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Replication-selective virotherapy for cancer: Biological principles, risk management and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

An adenovirus mutant that replicates selectively in p53-deficient human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Gene therapy death prompts review of adenovirus vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Gene therapy death--"everyone has to share in the guilt".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

21 January 2018

Gene therapy on trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Reovirus as a novel oncolytic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Reovirus therapy of tumors with activated Ras pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.CGT.7700539

Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy

21 January 2018

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Gene therapy setback.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Urea cycle disorders: diagnosis, pathophysiology, and therapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

ONYX-015: clinical data are encouraging

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/12522437

12 December 2020

Identifiers

DOI

10.1038/SJ.CGT.7700539

1 reference

6 August 2017

1 reference